Dr. rer. nat. Carolin Brandl

Sonderforschungsbereich/Transregio 130 B-Zellen: Immunität und Autoimmunität Professur für Genetik Department of Radiation Oncology Department of Medicine 3 – Rheumatology and Immunology

Epistatic effects of Siglec-G and DNase1 or DNase1l3 deficiencies in the development of systemic lupus erythematosus (2023) Korn M, Steffensen M, Brandl C, Royzman D, Daniel C, Winkler T, Nitschke L Journal article B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia (2022) Schmid VK, Khadour A, Ahmed N, Brandl C, Nitschke L, Rajewsky K, Jumaa H, Hobeika E Journal article Human CD22-transgenic, primary murine lymphoma challenges immunotherapies in organ-specific tumor microenvironments (2021) Gsottberger F, Brandl C, Wendland K, Petkovic S, Emmerich C, Erber R, Geppert CI, et al. Journal article A CD22-Shp1 phosphatase axis controls integrin beta(7) display and B cell function in mucosal immunity (2021) Ballet R, Brennan M, Brandl C, Feng N, Berri J, Cheng J, Ocon B, et al. Journal article Crossing the barriers: Revisiting the gut feeling in rheumatoid arthritis (2021) Brandl C, Bucci L, Schett G, Zaiss M Journal article, Review article Microbiota-induced Intestinal Barrier Dysfunction Initiates the Shuttling of Immune Cells from the Gut to the Joints (2020) Tajik N, Frech M, Brandl C, Canete J, Ciccia F, Schett G, Zaiss M Conference contribution A murine, myc-driven lymphoma model expressing human CD22 enables testing of targeted therapies and their effects on tumor immune microenvironment (2020) Gsottberger F, Brandl C, Petkovic S, Emmerich C, Nitschke L, Mackensen A, Müller F Conference contribution The B-cell inhibitory receptor CD22 is a major factor in host resistance to Streptococcus pneumoniae infection (2020) Fernandes VE, Ercoli G, Bénard A, Brandl C, Fahnenstiel H, Müller-Winkler J, Denny P, et al. Journal article Humanized CD22 transgenic mouse model for in vivo analysis of anti-CD22-based immunotherapy (2020) Brandl C, Angermüller S, Nitschke L Journal article A human CD22 transgenic, myc-driven lymphoma model to test effects of targeted therapies on lymphoma immune microenvironment in immunecompetent mice (2019) Wagner F, Brandl C, Petkovic S, Emmerich C, Nitschke L, Mackensen A, Müller F Conference contribution